臺北榮民總醫院口腔醫學部

:::

陳三奇 (San-Chi Chen)

複診掛號初診掛號

[簡介]

學歷
經歷
現職：
- - 迄今臺北榮民總醫院腫瘤醫學部腫瘤內科主治醫師
- - 迄今國立陽明交通大學醫學系內科學科助理教授
- - 迄今台灣免疫治療暨腫瘤學會秘書長
經歷：
- - 臺北榮民總醫院內科部血液腫瘤科主治醫師
- - 臺北榮民總醫院內科部血液腫瘤科總醫師
- - 臺北榮民總醫院內科部住院醫師
醫療專長
1. 肝癌、腸胃道腫瘤、骨肉瘤、免疫治療、精準醫療、臨床試驗
證照

中華民國腫瘤內科專科醫師、中華民國血液病專科醫師、中華民國血液及骨髓移植專科醫師、中華民國腫瘤安寧專科醫師、中華民國內科專科醫師
語言專長

國語台語英語

[著作]

Kim JS*, Wong J*, Chen SC*, Tai D, Yang H, Kim Y, Kang B, Kim I, Kim H, An C, Jang SJ, Kudo M, Lim HY, Kim C, Yau T, Chon HJ. Outcomes of Nivolumab plus Ipilimumab After Atezolizumab plus Bevacizumab in Advanced HCC: An International Multicenter Study. Liver Int. 2026 Feb;46(2):e70493 (First author, IF: 5.2, Gastroenterology & hepatology, 24/147=16.3%, Q1)
Huang JP, Tsai CK, Hsieh PY, Chen SC. Complete remission of hepatocellular carcinoma with atezolizumab and bevacizumab following prior B-cell depletion. 2026 Jan 1;49(1):25-28 (Corresponding author, IF: 2.9, Oncology, 153/326=46.9%, Q2)
Lu CH, Kao WY, Wu CH, Ting WY, Lu CH, Chuang KI, Ni CF, Hsieh YY, Wu MS, Su CW, Chen SC. Predicting Survival Outcomes in Patients with Hepatocellular Carcinoma Receiving Lenvatinib by Using the Up7-ALBI Score. Liver Cancer. 2025 Apr 29:1-14. (Corresponding author, IF: 11.6, Gastroenterology & hepatology, 10/143=7.0%, Q1)
Lai KC, Hsu TL, Lin SY, Chiang NJ, Chen MH, Chao Y, Yang MH, Chen SC. Real-world efficacy of cabozantinib alone or in combination with ICIs in heavily pretreated hepatocellular carcinoma: potential role of AXL and MET expression. Ann Hepatol. 2025 Apr 24:101917 (Corresponding author, IF: 4.4, Gastroenterology & hepatology, 28/147=19.0%, Q1)
Chen SC, Ho HL, Liu CA, Hung YP, Chiang NJ, Chen MH, Chao Y, Yang MH. PIVKA-II as a surrogate biomarker for therapeutic response in Non-AFP-secreting hepatocellular carcinoma. BMC Cancer. 2025 Feb 4;25(1):199 (First author, IF:3.4, Oncology, 118/325=36.3%, Q2)
Lai KC, Chen YH, Hung YP, Chiang NJ, Chen MH, Chen SC. Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy. Hepatol Int. 2024 Dec;18(6):1804-1814 (Corresponding author, IF: 6.1, Gastroenterology & hepatology, 20/147=13.6, Q1)
Chen SC. Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan. Clin Mol Hepatol. 2023 Apr;29(2):352-354. (Corresponding author, IF: 14, Gastroenterology & hepatology, 6/143, Q1)
Lai YH, Tung KC, Chen SC. Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report. Medicine (Baltimore). 2022 Sep 30;101(39):e30719. (Corresponding author, IF:1.81, Medicine, General&Internal,122/172, Q3)
Lai KC, Hsiao YH, Chen SC. Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review. Frontiers in immunology. 2022;13:994064.(Corresponding author, IF:8.78, Immunology, 33/161, Q1)
Wu WC, Lin TY, Chen MH, Hung YP, Liu CA, Lee RC, Huang YH, Chao Y, Chen SC. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Investigational new drugs. 2022;40(4):789-97. (Corresponding author, IF:3.65, Pharmacology&pharmacy,135/279=48.4%, Q2)
Chen SC, Huang YH, Chen MH, Hung YP, Lee RC, Shao YY, Chao Y. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. BMC cancer. 2022;22(1):55. (First author, IF:4.63, Oncology, 109/245, Q2)
Hsu CY, Su YW, Chen SC. Sick sinus syndrome associated with anti-programmed cell death-1. Journal for immunotherapy of cancer. 2018;6(1):72. (Corresponding author, IF:8.37, oncology and immunology,18/222, Q1)
Chen SC, Chao Y, Yang MH. Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report. The American journal of gastroenterology. 2017;112(4):659-60. (First author, IF:10.23, gastroenterology and hepatology ,6/80, Q1)